PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2

Molecular Oncology Division, National Cancer Center Research Institute, Tsukiji, Tokyo, Japan.
Nature medicine (Impact Factor: 27.36). 04/2010; 16(5):580-5, 1p following 585. DOI: 10.1038/nm.2122
Source: PubMed


Leukemias and other cancers possess self-renewing stem cells that help to maintain the cancer. Cancer stem cell eradication is thought to be crucial for successful anticancer therapy. Using an acute myeloid leukemia (AML) model induced by the leukemia-associated monocytic leukemia zinc finger (MOZ)-TIF2 fusion protein, we show here that AML can be cured by the ablation of leukemia stem cells. The MOZ fusion proteins MOZ-TIF2 and MOZ-CBP interacted with the transcription factor PU.1 to stimulate the expression of macrophage colony-stimulating factor receptor (CSF1R, also known as M-CSFR, c-FMS or CD115). Studies using PU.1-deficient mice showed that PU.1 is essential for the ability of MOZ-TIF2 to establish and maintain AML stem cells. Cells expressing high amounts of CSF1R (CSF1R(high) cells), but not those expressing low amounts of CSF1R (CSF1R(low) cells), showed potent leukemia-initiating activity. Using transgenic mice expressing a drug-inducible suicide gene controlled by the CSF1R promoter, we cured AML by ablation of CSF1R(high) cells. Moreover, induction of AML was suppressed in CSF1R-deficient mice and CSF1R inhibitors slowed the progression of MOZ-TIF2-induced leukemia. Thus, in this subtype of AML, leukemia stem cells are contained within the CSF1R(high) cell population, and we suggest that targeting of PU.1-mediated upregulation of CSF1R expression might be a useful therapeutic approach.

Download full-text


Available from: E. Richard Stanley,
    • "In healthy myeloid progenitors, MOZ binding to PU.1 is required for activation of M-CSFR expression [94]. Importantly, the leukemogenic fusion products MOZ-TIF2 and MOZ-CBP cause elevated M-CSFR expression [94]. Irf2, a member of the interferon regulatory factor family, represses interferon-mediated gene expression [95] [96]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cellular commitment to differentiation requires a tightly synchronized, spatial-temporal interaction of regulatory proteins with the basic DNA and chromatin. A complex network of mechanisms, involving induction of lineage instructive transcription factors, installation or removal of histone modifications and changes in the DNA methylation pattern locally orchestrate the three dimensional chromatin structure and determine cell fate. Maturation of myeloid lineages from haematopoietic stem cells has emerged as a powerful model to study those principles of chromatin mechanisms in cellular differentiation and lineage fate selection. This review summarizes recent knowledge and puts forward novel ideas on how dynamics in the epigenetic landscape of myeloid cells shape the development, immune-activation and leukaemic transformation outcome.
    Journal of Molecular Biology 08/2014; 427(3). DOI:10.1016/j.jmb.2014.08.015 · 4.33 Impact Factor
  • Source
    • "MOZ (monocytic leukemia zinc finger)-TIF2 fusion protein, a high level of CSF1R expression was shown to confer leukemia-initiating activity to myeloid cells (Aikawa et al., 2010). Despite the fact that miR-146a was predicted to target the CSF1R gene by multiple miRNA target prediction algorithms , we failed to detect direct interaction between miR-146a and the 3 UTR of the CSF1R gene, suggesting that upregulation of CSF1R expression on macrophage precursors in miR-146a–null mice may be mediated by an intermediate factor. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Excessive or inappropriate activation of the immune system can be deleterious to the organism, warranting multiple molecular mechanisms to control and properly terminate immune responses. MicroRNAs (miRNAs), ∼22-nt-long noncoding RNAs, have recently emerged as key posttranscriptional regulators, controlling diverse biological processes, including responses to non-self. In this study, we examine the biological role of miR-146a using genetically engineered mice and show that targeted deletion of this gene, whose expression is strongly up-regulated after immune cell maturation and/or activation, results in several immune defects. Collectively, our findings suggest that miR-146a plays a key role as a molecular brake on inflammation, myeloid cell proliferation, and oncogenic transformation.
    Journal of Experimental Medicine 06/2011; 208(6):1189-201. DOI:10.1084/jem.20101823 · 12.52 Impact Factor
  • Source
    • "Figure 1A shows the mRNA levels of candidate LSC-specific surface molecules in purified CD34 + CD38 À AML cells and normal HSCs. The molecules expressed in CD34 + CD38 À AML cells at levels >8-fold higher as compared to normal HSCs included TIM-3 and previously identified LSC-specific molecules such as CLL-1 (van Rhenen et al., 2007), CSF1R (Aikawa et al., 2010), and CD96 (Figure 1A; Hosen et al., 2007). As shown in Figure 1B, TIM-3 protein was highly expressed in CD34 + CD38 À AML cells but not in normal HSCs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute myeloid leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), an ultimate therapeutic target for AML. Here we identified T cell immunoglobulin mucin-3 (TIM-3) as a surface molecule expressed on LSCs in most types of AML except for acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). TIM-3(+) but not TIM-3⁻ AML cells reconstituted human AML in immunodeficient mice, suggesting that the TIM-3(+) population contains most, if not all, of functional LSCs. We established an anti-human TIM-3 mouse IgG2a antibody having complement-dependent and antibody-dependent cellular cytotoxic activities. This antibody did not harm reconstitution of normal human HSCs, but blocked engraftment of AML after xenotransplantation. Furthermore, when it is administered into mice grafted with human AML, this treatment dramatically diminished their leukemic burden and eliminated LSCs capable of reconstituting human AML in secondary recipients. These data suggest that TIM-3 is one of the promising targets to eradicate AML LSCs.
    Cell stem cell 12/2010; 7(6):708-17. DOI:10.1016/j.stem.2010.11.014 · 22.27 Impact Factor
Show more